Glucagon Interactions: Alcohol, Caffeine, Food and Other Compounds

Questions about glucagon and other substances usually assume that a controlled interaction study exists. For most pairings — glucagon with alcohol, glucagon with caffeine, glucagon with common supplements — that assumption does not hold in the published record summarised here. This page groups every interaction-style question into one place, states where evidence exists, and flags clearly where the only available answer is mechanistic reasoning rather than measurement.

What "Interaction" Means in the Glucagon Literature

Glucagon is a pancreatic hormone whose best-characterised action is on hepatic glucose production. A 2025 paper in Peptides examined how glucagon acutely stimulates hepatic gluconeogenesis, describing the liver as the primary site through which the hormone raises circulating glucose (PMID 41093268). Because that pathway is hepatic and glucose-centred, researchers reason that anything which alters liver substrate availability, hepatic metabolism or counterregulatory signalling is where an interaction would most plausibly appear — but reasoning of that kind is not the same as a trial result.

A second complication: much of the modern peptide literature that readers encounter under the word "glucagon" is actually about glucagon-like peptide-1 (GLP-1), a structurally related but functionally distinct gut hormone, or about dual and triple agonists that include a glucagon receptor component. A 2022 review in Molecular Metabolism set out how GLP-1 physiology informs the pharmacotherapy of obesity, including the move toward multi-receptor molecules (PMID 34626851). Findings about GLP-1 receptor agonists are not automatically findings about glucagon itself, and this page labels which hormone each cited paper addressed.

Glucagon and Alcohol: What the Literature Covers

No controlled trial in this citation set administered glucagon alongside alcohol and measured a pharmacological interaction. What the literature does contain is two adjacent bodies of work.

Alcohol as a nutrient and appetite signal

A 2003 review in Current Opinion in Clinical Nutrition and Metabolic Care addressed alcohol and food intake, examining how alcohol consumption relates to energy intake and appetite regulation (PMID 14557794). That review sits on the nutrition side of the question rather than the peptide side; it did not administer glucagon.

Gut hormones and alcohol consumption

Several reviews have asked whether gut hormone signalling influences drinking behaviour. A 2022 review in the British Journal of Pharmacology examined the role of GLP-1 in addictive disorders (PMID 34532853), and a 2024 review in European Addiction Research asked whether gut hormones act as possible mediators of addictive disorders (PMID 39389039). A 2023 commentary in Nature Medicine described GLP-1 receptor agonists as promising but unproven treatments for alcohol and substance use disorders, a framing that explicitly separates preclinical signal from clinical proof (PMID 38001271). A 2024 article in CNS Spectrums asked whether GLP-1 receptor agonists are anti-consummatory drugs — that is, whether their effects extend beyond food to other consumed substances (PMID 39801083). A 2025 German-language review in Der Nervenarzt surveyed GLP-1 receptor agonists as a possible pharmacological option in psychiatric illness (PMID 40042613).

Summary of this section: the reviews above concern GLP-1 receptor agonism and alcohol-related behaviour, and the Nature Medicine piece characterised that evidence base as unproven (PMID 38001271). None of them reported a glucagon–alcohol co-administration experiment.

Mechanistic reasoning (labelled as reasoning, not evidence)

Researchers describing glucagon's biology note that its glucose-raising action depends on hepatic gluconeogenesis (PMID 41093268). From that physiology, investigators infer that conditions which limit hepatic gluconeogenic capacity would blunt a glucagon-driven glucose rise. That inference is standard textbook reasoning about liver metabolism; it has not been tested as a glucagon–alcohol interaction study within the papers cited here, and this page does not present it as a measured finding.

Glucagon and Caffeine

The verified literature for this page contains no study that administered caffeine with glucagon, measured caffeine's effect on glucagon pharmacokinetics, or tracked glucose responses to the combination. That absence is stated plainly rather than filled with inference dressed up as data.

The mechanistic reasoning researchers apply — again, reasoning rather than measurement — starts from the fact that glucagon's acute output is hepatic glucose release (PMID 41093268), and that caffeine is a stimulant with its own documented effects on catecholamine signalling and glucose handling in the general physiology literature. Whether those two influences add, oppose or do nothing to one another is an empirical question that the papers summarised here did not answer.

Food, Fasting and Meal Timing

Food state is the single most relevant "interaction" variable in glucagon physiology, because glucagon is a counterregulatory hormone whose role rises when exogenous glucose supply falls. The 2025 Peptides paper examined the acute stimulation of hepatic gluconeogenesis by glucagon, the pathway that becomes central during fasting (PMID 41093268).

On the intake side, the 2003 review of alcohol and food intake examined how one ingested substance relates to overall energy consumption (PMID 14557794). In the incretin literature, a 2024 review in Cells asked whether incretin agonism has sustainable efficacy, examining durability of effect over time (PMID 39594592), and the 2022 Molecular Metabolism review connected GLP-1 physiology — including its effects on intake and gastric handling — to obesity pharmacotherapy (PMID 34626851). Those are GLP-1 findings; they describe a different receptor system from the glucagon receptor, even though multi-agonist drugs engage both.

Commonly Asked Compound Combinations

Combination obesity pharmacotherapy

A 2018 review in Metabolic Syndrome and Related Disorders examined combination therapies for obesity, the general strategy of pairing agents with different mechanisms (PMID 29993319). The 2022 Molecular Metabolism review described how GLP-1 physiology shaped the design of subsequent obesity pharmacotherapy, including combination and multi-receptor approaches (PMID 34626851), while the 2024 Cells review addressed whether the efficacy of incretin agonism is sustained (PMID 39594592).

Gastrointestinal disease contexts

A 2025 review in Biomolecules examined gut hormones in the context of inflammatory bowel disease, covering how enteroendocrine signalling intersects with intestinal inflammation (PMID 40723884). That work describes a disease context rather than a drug–drug interaction.

Pregnancy

A 2025 paper in Diabetes, Obesity and Metabolism reported safety data on GLP-1 receptor agonist use during pregnancy drawn from regulatory clinical trials (PMID 40329607). It concerned GLP-1 receptor agonists, not glucagon, and is included here because it is frequently retrieved under adjacent queries.

Reported Adverse Events in Combination Contexts: What Studies Report

No paper in this citation set reported an adverse event arising specifically from combining glucagon with alcohol, caffeine or a dietary supplement. The closest relevant material is tolerability discussion inside the incretin literature: the 2018 combination-therapy review discussed the trade-offs of pairing anti-obesity agents (PMID 29993319), the 2024 Cells review addressed durability and the limits of incretin agonism (PMID 39594592), and the 2025 pregnancy analysis drew its safety signals from regulatory trial datasets rather than from interaction experiments (PMID 40329607). Readers comparing these sources should note that each describes a different molecule class and a different clinical setting.

Evidence Map

How to Read Absence of Evidence

Three distinctions matter when interpreting this page:

• No study ≠ no effect. The absence of a glucagon–caffeine trial in this set means nothing was measured, not that nothing happens.
• Mechanism ≠ outcome. The 2025 Peptides work described a hepatic pathway (PMID 41093268); pathway descriptions do not predict what happens when a second substance is introduced.
• GLP-1 ≠ glucagon. The alcohol-related reviews in this set examined GLP-1 receptor agonism (PMID 34532853, PMID 39801083), a separate receptor system.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or hormone. Nothing here describes a protocol, and no combination is characterised as appropriate or inappropriate — only as studied or unstudied in the papers listed below.

References

• Glucagon acutely stimulates hepatic gluconeogenesis (Peptides, 2025)
• Alcohol and food intake (Current Opinion in Clinical Nutrition and Metabolic Care, 2003)
• The role of glucagon-like peptide 1 (GLP-1) in addictive disorders (British Journal of Pharmacology, 2022)
• GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders (Nature Medicine, 2023)
• Gut Hormones: Possible Mediators of Addictive Disorders? (European Addiction Research, 2024)
• Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs? (CNS Spectrums, 2024)
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (Der Nervenarzt, 2025)
• GLP-1 physiology informs the pharmacotherapy of obesity (Molecular Metabolism, 2022)
• Combination Therapies for Obesity (Metabolic Syndrome and Related Disorders, 2018)
• Does Incretin Agonism Have Sustainable Efficacy? (Cells, 2024)
• Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials (Diabetes, Obesity & Metabolism, 2025)
• Gut Hormones and Inflammatory Bowel Disease (Biomolecules, 2025)